PROJ-SUN_1170x120_6-24-20

Dr. Vas Narasimhan

Novartis seeks approval to spinoff Alcon eye care biz

Novartis seeks approval to spinoff Alcon eye care biz

BASEL — Novartis today announced its intention to spinoff Alcon, its eye care division, into a separately-traded standalone company. The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies. Completion of the transaction is subject to general market conditions, tax rulings and opinions, final Board of Directors endorsement and shareholder